Daptomycin-resistant Enterococcus faecium in a patient with acute myeloid leukemia

Jennifer K. Long, Toni K. Choueiri, Geraldine S. Hall, Robin Avery, Mikkael A. Sekeres

Research output: Contribution to journalArticle

Abstract

Daptomycin is a lipopeptide antimicrobial used for the treatment of aerobic gram-positive skin and soft tissue infections. We describe a patient with acute myeloid leukemia whose febrile neutropenia was treated with daptomycin and who later developed daptomycin-resistant Enterococcus faecium infection. Defervescence and negative blood cultures ensued after treatment with linezolid. Guidelines for testing daptomycin susceptibilities of enterococci include breakpoints only for vancomycin-susceptible Enterococcus faecalis, making interpretation of minimum inhibitory concentrations for common clinical infections difficult. No enterococcal cross-resistance has been reported among daptomycin, linezolid, or quinupristin-dalfopristin, and these agents may be viable alternatives.

Original languageEnglish (US)
Pages (from-to)1215-1216
Number of pages2
JournalMayo Clinic Proceedings
Volume80
Issue number9
StatePublished - 2005
Externally publishedYes

Fingerprint

Daptomycin
Enterococcus faecium
Linezolid
Acute Myeloid Leukemia
Lipopeptides
Febrile Neutropenia
Soft Tissue Infections
Enterococcus faecalis
Enterococcus
Microbial Sensitivity Tests
Vancomycin
Infection
Guidelines
Skin
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Long, J. K., Choueiri, T. K., Hall, G. S., Avery, R., & Sekeres, M. A. (2005). Daptomycin-resistant Enterococcus faecium in a patient with acute myeloid leukemia. Mayo Clinic Proceedings, 80(9), 1215-1216.

Daptomycin-resistant Enterococcus faecium in a patient with acute myeloid leukemia. / Long, Jennifer K.; Choueiri, Toni K.; Hall, Geraldine S.; Avery, Robin; Sekeres, Mikkael A.

In: Mayo Clinic Proceedings, Vol. 80, No. 9, 2005, p. 1215-1216.

Research output: Contribution to journalArticle

Long, JK, Choueiri, TK, Hall, GS, Avery, R & Sekeres, MA 2005, 'Daptomycin-resistant Enterococcus faecium in a patient with acute myeloid leukemia', Mayo Clinic Proceedings, vol. 80, no. 9, pp. 1215-1216.
Long, Jennifer K. ; Choueiri, Toni K. ; Hall, Geraldine S. ; Avery, Robin ; Sekeres, Mikkael A. / Daptomycin-resistant Enterococcus faecium in a patient with acute myeloid leukemia. In: Mayo Clinic Proceedings. 2005 ; Vol. 80, No. 9. pp. 1215-1216.
@article{1eaa57edbd39445a9d98008695afbad2,
title = "Daptomycin-resistant Enterococcus faecium in a patient with acute myeloid leukemia",
abstract = "Daptomycin is a lipopeptide antimicrobial used for the treatment of aerobic gram-positive skin and soft tissue infections. We describe a patient with acute myeloid leukemia whose febrile neutropenia was treated with daptomycin and who later developed daptomycin-resistant Enterococcus faecium infection. Defervescence and negative blood cultures ensued after treatment with linezolid. Guidelines for testing daptomycin susceptibilities of enterococci include breakpoints only for vancomycin-susceptible Enterococcus faecalis, making interpretation of minimum inhibitory concentrations for common clinical infections difficult. No enterococcal cross-resistance has been reported among daptomycin, linezolid, or quinupristin-dalfopristin, and these agents may be viable alternatives.",
author = "Long, {Jennifer K.} and Choueiri, {Toni K.} and Hall, {Geraldine S.} and Robin Avery and Sekeres, {Mikkael A.}",
year = "2005",
language = "English (US)",
volume = "80",
pages = "1215--1216",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "9",

}

TY - JOUR

T1 - Daptomycin-resistant Enterococcus faecium in a patient with acute myeloid leukemia

AU - Long, Jennifer K.

AU - Choueiri, Toni K.

AU - Hall, Geraldine S.

AU - Avery, Robin

AU - Sekeres, Mikkael A.

PY - 2005

Y1 - 2005

N2 - Daptomycin is a lipopeptide antimicrobial used for the treatment of aerobic gram-positive skin and soft tissue infections. We describe a patient with acute myeloid leukemia whose febrile neutropenia was treated with daptomycin and who later developed daptomycin-resistant Enterococcus faecium infection. Defervescence and negative blood cultures ensued after treatment with linezolid. Guidelines for testing daptomycin susceptibilities of enterococci include breakpoints only for vancomycin-susceptible Enterococcus faecalis, making interpretation of minimum inhibitory concentrations for common clinical infections difficult. No enterococcal cross-resistance has been reported among daptomycin, linezolid, or quinupristin-dalfopristin, and these agents may be viable alternatives.

AB - Daptomycin is a lipopeptide antimicrobial used for the treatment of aerobic gram-positive skin and soft tissue infections. We describe a patient with acute myeloid leukemia whose febrile neutropenia was treated with daptomycin and who later developed daptomycin-resistant Enterococcus faecium infection. Defervescence and negative blood cultures ensued after treatment with linezolid. Guidelines for testing daptomycin susceptibilities of enterococci include breakpoints only for vancomycin-susceptible Enterococcus faecalis, making interpretation of minimum inhibitory concentrations for common clinical infections difficult. No enterococcal cross-resistance has been reported among daptomycin, linezolid, or quinupristin-dalfopristin, and these agents may be viable alternatives.

UR - http://www.scopus.com/inward/record.url?scp=24144466852&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24144466852&partnerID=8YFLogxK

M3 - Article

VL - 80

SP - 1215

EP - 1216

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 9

ER -